The Week in Review: April 28, 2017 – May 5, 2017

Friday, May 5, 2017 News Recap Canada Great news from Nova Scotia: Expanded access to and coverage for treatment of chronic hepatitis C is now available under the provincial Pharmacare plan, similar to the new arrangements in BC, Alberta, Ontario, Saskatchewan and Quebec.  The drugs covered are: Epclusa, Daklinza, Sunvepra, Zepatier, Harvoni and Sovaldi. You can read the Nova Scotia Pharmacare Formulary Updates here (Nova Scotia Lists EPCLUSA™ on P...

Nova Scotia Lists EPCLUSA™ on Public Drug Plan to Treat All Six Genotypes of Chronic Hepatitis C Infection

Nova Scotia Also Broadens Access for Patients with Less Advanced Disease Who Have Other Health Conditions MISSISSAUGA, ON, May 1, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective immediately, Nova Scotia will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Nova Scotia: New drug will help with hepatitis C treatment

Nova Scotians will soon have access to a new drug to help treat hepatitis C. Nova Scotia’s Department of Health and Wellness announced Monday the province will provide public access to EPCLUSA tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C. With this drug, patients take one tablet daily for 12 weeks, provided they are adult patients without cirrhosis or with compensat

The Week in Review: April 14, 2017 – April 21, 2017

Friday, April 21, 2017 News Recap Canada Well the last report from the final leg of HepCBC’s Road Trip to BC’s Interior 2017 is in. What a journey!! – and so much work!! This report focusses on events in the Kootenay region of BC, and I’m really impressed at how much Rosemary and Cheryl were able to accomplish!  Amazing. Awareness of hepatitis C in BC’s more remote and small communities is growing and this is due to the hard work of the many advocat...

Organizations hope better access to meds halts spread of hepatitis C

Some Thunder Bay, Ont. organizations treating hepatitis C patients say the province's move to improve access to curative drugs for the disease could help stop its spread. "It's an exciting time," said Holly Gauvin, the executive director of Elevate NWO, a group that supports hepatitis C and HIV/AIDS patients. Thunder Bay has some of the highest hepatitis C infection rates in Ontario, according to public health officials. Until now, only patients wit

The Week in Review: March 31, 2017 – April 7, 2017

Friday, April 7, 2017 News Recap Canada Effective April 2017, Alberta Health has expanded access to treatments for hepatitis C in line with what the provinces of British Columbia, Ontario, Saskatchewan, and Québec have just done (Alberta expands drug coverage for hepatitis C patients). As Dr. Shafran, who is clearly worried about continued restrictions, says, “The funders have now opened the doors to let us treat people with mild liver disease … if ...

Wiping out hepatitis C: Alberta doctor explains access to game-changing drug for patients

More Albertans suffering from hepatitis C will receive treatment thanks to public funding for new therapies, says Stephen Shafran, a University of Alberta professor of medicine who specializes in the virus. He spoke Wednesday to Postmedia about a game-changing drug and how Alberta can help eradicate hepatitis C. Here’s a condensed, edited version the interview. Q: Alberta Health has made the drug Epclusa available to more patients. The treatment is a p

The Week in Review: Feb 17, 2017 – Feb 24, 2017

Friday, February 24, 2017 News Recap Better Public Access to New HepC Meds Announced in Canada This week the pan-Canadian Pharmaceutical Alliance (pCPA), on behalf of participating federal, provincial and territorial public drug plans, concluded successful negotiations with three drug manufacturers to help jurisdictions expand access to publicly funded medications for the treatment of chronic hepatitis C. What this Means: Immediately following th...

Ontario and British Columbia expand treatment access to chronic hepatitis C (CHC) patients

Effective February 28, Ontario will become the first province to reimburse ZEPATIER®  (elbasvir/grazoprevir), a simple one pill, once daily, 12 week no ribavirin regimen for most patients, and will be followed by British Columbia on March 21 In addition to patients with liver fibrosis stage F2+, patients with liver fibrosis stage F0 and F1 with poor prognostic factors, who had no public access to a potential cure under existing public plans, a...